Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0K6UI
|
||||
Former ID |
DPR000165
|
||||
Drug Name |
Galardin
|
||||
Synonyms |
Ilomastat; Galardin MPI; Ilomastat [USAN]; CS 610; GM 6001; CS-610; Ilomastat (USAN/INN); N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (2R)-N'-hydroxy-N-[(2S)-3-(1H-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup 1)-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl)-2-(2-methylopropyl)butanediamide
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Corneal ulcers [ICD9: 370; ICD10:H16.0] | Discontinued in Phase 2 | [544872] | ||
Therapeutic Class |
Antiinflammatory Agents
|
||||
Company |
Glycomed
|
||||
Structure |
Download2D MOL |
||||
Formula |
C20H28N4O4
|
||||
Canonical SMILES |
CC(C)CC(CC(=O)NO)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC
|
||||
InChI |
1S/C20H28N4O4/c1-12(2)8-13(10-18(25)24-28)19(26)23-17(20(27)21-3)9-14-11-22-16-7-5-4-6-15(14)16/h4-7,11-13,17,22,28H,8-10H2,1-3H3,(H,21,27)(H,23,26)(H,24,25)/t13-,17+/m1/s1
|
||||
InChIKey |
NITYDPDXAAFEIT-DYVFJYSZSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
829892, 10243138, 11120050, 11120538, 11121026, 11121715, 11122195, 11147133, 11362833, 11365395, 11367957, 11370897, 11370898, 11373558, 11376119, 12014779, 14878422, 14902905, 17397881, 24902217, 26756835, 26758815, 29310648, 46484604, 46506673, 47364924, 47588747, 48034840, 48258955, 48427395, 50070501, 50071141, 50111444, 50111445, 53790355, 57344178, 79412811, 81060888, 81062449, 81062451, 92310066, 99029951, 99300978, 99302498, 103185416, 103957874, 104377641, 121379601, 124892442, 134340919
|
||||
Target and Pathway | |||||
Target(s) | Stromelysin-1 | Target Info | Inhibitor | [528485], [529239] | |
NetPath Pathway | IL1 Signaling Pathway | ||||
IL4 Signaling Pathway | |||||
PANTHER Pathway | Plasminogen activating cascade | ||||
CCKR signaling map ST | |||||
References | |||||
Ref 528485 | Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats. Scand J Gastroenterol. 2006 Nov;41(11):1320-9. | ||||
Ref 529239 | Novel transcription-factor-like function of human matrix metalloproteinase 3 regulating the CTGF/CCN2 gene. Mol Cell Biol. 2008 Apr;28(7):2391-413. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.